Eledon Pharmaceuticals (ELDN) Operating Leases (2019 - 2026)
Eledon Pharmaceuticals (ELDN) posted Operating Leases of $186000.0 for Q1 2026, down 34.28% on a QoQ basis from $283000.0 in Q4 2025, and down 66.49% year-over-year from $555000.0 in Q1 2025.
Eledon Pharmaceuticals (ELDN) Operating Leases (2019 - 2026) Analysis & Trends
Eledon Pharmaceuticals' Operating Leases history runs 8 years deep, the most recent figure standing at $186000.0 for Q1 2026.
- Quarterly Operating Leases fell 66.49% year-over-year to $186000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $186000.0 (down 66.49% YoY) and the FY2025 annual result came in at $283000.0, down 55.78% from the prior year.
- Operating Leases was $186000.0 for Q1 2026 at Eledon Pharmaceuticals, down from $283000.0 in the prior quarter.
- Across five years, Operating Leases topped out at $640000.0 in Q4 2024 and bottomed at $83000.0 in Q3 2023.
- A 5-year average of $350133.3 and a median of $350000.0 in 2022 frame the typical range for Operating Leases.
- Annual changes were most pronounced in 2022 — Operating Leases surged 924.44% — and 2023, when it sank 82.0%.
- Eledon Pharmaceuticals' Operating Leases stood at $383000.0 in 2022, then plunged by 78.33% to $83000.0 in 2023, then surged by 671.08% to $640000.0 in 2024, then slumped by 55.78% to $283000.0 in 2025, then slumped by 34.28% to $186000.0 in 2026.
- Business Quant data shows ELDN's Operating Leases at $186000.0 in Q1 2026, $283000.0 in Q4 2025, and $376000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,861.65 Bn | 66,861.36 Bn | - |
| 2 | Nanobiotix | 1,912.79 Bn | 1,912.72 Bn | - |
| 3 | Akari Therapeutics | 1,071.19 Bn | 1,071.19 Bn | - |
| 4 | BeOne Medicines | 469.11 Bn | 464.32 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 123.03 Bn | 115.78 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 70.13 Bn | 61.37 Bn | 3.31 Bn |
| 7 | Belite Bio | 63.44 Bn | 63.44 Bn | - |
| 8 | Argenx Se | 55.97 Bn | 50.78 Bn | 1.41 Bn |
| 9 | Alnylam Pharmaceuticals | 37.53 Bn | 34.52 Bn | 959.66 Mn |
| 10 | Eledon Pharmaceuticals | 407.54 Mn | 407.54 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 186,000.00 |
| Dec 31, 2025 | 283,000.00 |
| Sep 30, 2025 | 376,000.00 |
| Jun 30, 2025 | 467,000.00 |
| Mar 31, 2025 | 555,000.00 |
| Dec 31, 2024 | 640,000.00 |
| Sep 30, 2024 | 315,000.00 |
| Jun 30, 2024 | 386,000.00 |
| Sep 30, 2023 | 83,000.00 |
| Jun 30, 2023 | 184,000.00 |
| Mar 31, 2023 | 284,000.00 |
| Dec 31, 2022 | 383,000.00 |
| Sep 30, 2022 | 461,000.00 |
| Jun 30, 2022 | 299,000.00 |
| Mar 31, 2022 | 350,000.00 |
| Dec 31, 2021 | 400,000.00 |
| Sep 30, 2021 | 45,000.00 |
| Jun 30, 2021 | 90,000.00 |
| Jun 30, 2020 | 48,000.00 |
| Mar 31, 2020 | 97,000.00 |